Volume 5.26 | Jul 18 - Prostate Cell News

Prostate Cell News 5.26 July 18, 2014

TOP STORY

Anti-Cancer Activity of Curcumin Loaded Nanoparticles in Prostate Cancer
Researchers indicated that poly(lactic-co-glycolic acid)- curcumin (CUR) nanoparticles efficiently internalize in prostate cancer cells and release biologically active CUR in cytosolic compartment of cells for effective therapeutic activity. [Biomaterials] Abstract

Request Sample: ReLeSR™, Easy Passaging Through Selective Detachment of hPSCs

PUBLICATIONS (Ranked by impact factor of the journal)

LABORATORY RESEARCH

Loss of PTEN Stabilizes the Lipid Modifying Enzyme Cytosolic Phospholipase A₂α via AKT in Prostate Cancer Cells
Researchers examined whether AKT plays a role in promoting cPLA₂α action in prostate cancer cells. They found a concordant increase in pAKT and cytosolic phospholipase A₂α (cPLA₂α) levels in prostate tissue of prostate epithelial-specific PTEN-knockout but not PTEN-wide type mice. [Oncotarget] Full Article

Discovery of 1H-Indole-2-Carboxamides as Novel Inhibitors of the Androgen Receptor Binding Function 3 (BF3)
A library of 1H-indole-2-carboxamides were discovered as BF3 inhibitors and exhibited strong anti-proliferative activity against both LNCaP and enzalutamide-resistant prostate cancer cell lines. [J Med Chem] Abstract

Autoregulatory Feedback Loop of EZH2/miR-200c/E2F3 as a Driving Force for Prostate Cancer Development
The depletion of enhancer of zeste homolog 2 (EZH2) in cell experiments inhibited prostate cancer cell growth and blocked cell cycle accompanying the downregulation of E2F3 expression. [Biochim Biophys Acta] Abstract

Important Role of SUMOylation of Spliceosome Factors in Prostate Cancer Cells
Using SI2 as a way of inhibiting the activity of sentrin/SUMO (small ubiquitin-like modifier)-specific proteases and the SUMO stably-transfected PC3 cells as a prostate cancer model, in combination with the stable isotope labeling with amino acids quantitative proteomic technique, scientists identified more than 900 putative target proteins of SUMO, in which 231 proteins were further subjected to bioinformatic analysis. [J Proteome Res] Abstract

The Long Noncoding RNAs PCAT29 Inhibits Oncogenic Phenotypes in Prostate Cancer
Prostate cancer-associated transcript 29 (PCAT29) knockdown significantly increased proliferation and migration of prostate cancer cells, while PCAT29 overexpression conferred the opposite effect and suppressed growth and metastases of prostate tumors in chick chorioallantoic membrane assays. [Mol Cancer Res] Abstract

Mitogen-Activated Protein Kinase Kinase 4 (MAP2K4) Promotes Human Prostate Cancer Metastasis
Researchers engineered human prostate cancer cell lines which overexpress either wild type or constitutive active MAP2K4. In vitro studies establish stable MAP2K4 overexpression promotes cell invasion, but does not affect cell growth or migration. [PLoS One] Full Article

MLN2238 Synergizes BH3 Mimetic ABT-263 in Castration-Resistant Prostate Cancer Cells by Induction of NOXA
The antitumor efficacy of ABT-263 and MLN2238 were evaluated as single agents and in combination in four castration-resistant prostate cancer (CRPC) cell lines: PC3, C4-2B, C4-2, and DU145. Scientists found that ABT-263 and MLN2238 alone exhibited a mild cytotoxicity, and in combination, they elicited a synergistic cytotoxic effect in CRPC cells. [Tumor Biol] Abstract

The Influence of Monoacylglycerol Lipase Inhibition upon the Expression of Epidermal Growth Factor Receptor in Human PC-3 Prostate Cancer Cells
It has been reported that direct activation of the cannabinoid CB1 receptor in epidermal growth factor-stimulated PC-3 prostate cancer cells results in an anti-proliferative effect accompanied by a down-regulation of epidermal growth factor receptors. Scientists investigated whether similar effects are seen following inhibition of the endocannabinoid hydrolytic enzyme monoacylglycerol lipase. [BMC Res Notes] Abstract | Full Article

CLINICAL RESEARCH

Fifteen-Year Survival Outcomes following Primary Androgen-Deprivation Therapy for Localized Prostate Cancer
The authors determined the long-term survival impact of primary androgen-deprivation therapy (ADT) in older men with localized prostate cancer. With a median follow-up of 110 months, primary ADT was not associated with improved 15-year overall or prostate cancer-specific survival following the diagnosis of localized prostate cancer. [JAMA Intern Med] Abstract | Press Release

Phase I Safety and Pharmacodynamic of Inecalcitol, a Novel VDR Agonist with Docetaxel in Metastatic Castration-Resistant Prostate Cancer Patients
Scientists conducted a Phase I multicenter trial in naïve metastatic CRPC patients with escalating inecalcitol dosages, combined to docetaxel-based chemotherapy. Safety and efficacy were evaluated in groups of three to six patients receiving inecalcitol during a 21-day cycle in combination with docetaxel and oral prednisone up to six cycles. [Clin Cancer Res] Abstract

Population-Based Analysis of Treatment Modalities and Survival for Clinically Localized Small-Cell Carcinoma of the Prostate
Researchers determined the treatment patterns and evaluated factors affecting overall survival for patients with localized small-cell carcinoma of the prostate. [Prostate Cancer Prostatic Dis] Abstract

[Free On-Demand Webinar] Detect Cancer Stem Cells with ALDEFLUOR™ - Watch Now

REVIEWS

The Role of Estrogen Receptor Beta in Prostate Cancer
Estrogen receptor beta (ERβ) is a promising target as an anticancer therapy and prevention for prostate cancer. The authors review the recent experimental findings of ERβ signaling in prostate. [Mol Med] Full Article

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

INDUSTRY NEWS

The Ontario Institute for Cancer Research Congratulates Dr. John Bartlett and Team on Receiving a $5 Million Movember Team Grant
Dr. Tom Hudson, President and Scientific Director of the Ontario Institute for Cancer Research, congratulated Dr. John Bartlett and his collaborators on receiving a 2014 Movember Team Grant for prostate cancer research. [Ontario Institute for Cancer Research] Press Release

NW Bio Announces Completion of DCVAX^®-Direct Phase I Trial Recruitment
Northwest Biotherapeutics announced that the Phase I portion of the Company’s Phase I/II DCVax-Direct clinical trial has completed its 36-patient target recruitment, and the company is now underway with preparations for the Phase II portion of this trial, as well as expansion of DCVax-Direct manufacturing. The Phase I/II trial is testing the safety and activity of DCVax-Direct in various types of cancer. [Northwest Biotherapeutics, Inc.]
Press Release

From our sponsor:
Interested in assays for human mammary stem and progenitor cells? Request your free wallchart.

POLICY NEWS

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

EVENTS

NEW Targeting the PI3K-mTOR Network in Cancer
September 14-17, 2014
Philadelphia, United States

Visit our events page to see a complete list of events in the prostate cell community.

JOB OPPORTUNITIES

NEW Product Marketing Manager (Cesca Therapeutics)

NEW Postdoctoral Position – Cancer Biology/Genomics (Cornell University)

NEW Postgraduate Position – Investigation into Chemokine Receptor Induced Cell Migration (University of East Anglia)

NEW Postdoctoral Research Fellow – Mechanism of Gene Regulation in Prostate Cancer Development and Bone Metastasis (Brigham & Women’s Hospital – Harvard Medical School)

NEW PhD Studentship – Cancer Cell Biology (Queensland University of Technology – Translational Research Institute)

NEW Associate Research Scientist – Molecular Mechanisms that Regulate Prostate Tumor Initiation and Formation of Cancer Stem Cells (Columbia University)

Postdoctoral Fellow – Computational Biology (Netherlands Cancer Institute)

Postdoctoral Fellow – Prostate Cancer Research (Institute of Oncology Research)

PhD Student – Detection of Novel Prostate Cancer Biomarkers (University of Bath)

Postdoctoral Fellow – Translational Prostate Cancer (Cleveland Clinic)

Postdoctoral Fellow – Prostate Cancer Research (Henry Ford Hospital)

Scientist – Prostate Cell Research (STEMCELL Technologies Inc.)

Scientist – Pluripotent Stem Cell Media Development: High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here

Learn more about Prostate Cell News: Archives | Events | Contact Us